FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine. 1. Using 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione or its pharmaceutically acceptable salts for preparing a drug for treating, preventing or arresting the developing diabetes-related complications - nephropathy, neuropathy or cardiomyopathy. The method of treating or preventing diabetic nephropathy, neuropathy or cardiomyopathy, or arresting the development consisting in introducing an effective amount of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione, or its pharmaceutically acceptable salts in a subject in need thereof. A pharmaceutical composition for treating or preventing the diabetes-related complications contains 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione or its pharmaceutically acceptable salts mixed with one or more pharmaceutically acceptable diluents or carriers wherein the complication is specified in nephropathy, neuropathy or cardiomyopathy. The pharmaceutical composition contains a) a first agent which is specified in 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione or its pharmaceutically acceptable salts, and b) at least one active ingredient which is specified in a group consisting of one compound increasing HDL level, a δ-PPAR compound, a non-glitazone γ-PPAR agonist, an antihypertensive agent, a cholesterol absorption modulator, an apo-A1 analogue or mimetic, a rennin inhibitor, a thrombin inhibitor, an aldosterone inhibitor, a GLP-1 agonist, a glucagon receptor antagonist, a cannabinoid receptor 1 antagonist, an antiobesity agent, a thrombocyte aggregation inhibitor, a PPAR agonist, a prosclerotic growth factor or their pharmaceutically acceptable salts. The method of treating or preventing diabetes or the diabetes-related complications, or arresting the development which consists in the combined introduction e.g. simultaneously or sequentially, of the therapeutically effective amount of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione or its pharmaceutically acceptable salts, and the second drug into the subject in need thereof wherein the second drug is specified in a group consisting of a compound increasing HDL level, an antidiabetic agent, an antihypertensive agent, a cholesterol absorption modulator, an apo-A1 analogue or mimetic, a rennin inhibitor, a thrombin inhibitor, an aldosterone inhibitor, a GLP-1 agonist, a glucagon receptor antagonist, a cannabinoid receptor 1 antagonist, an antiobesity agent, a thrombocyte aggregation inhibitor, a PPAR agonist, a DPP-IV inhibitor, a prosclerotic growth factor or their pharmaceutically acceptable salts.
EFFECT: group of invention provides higher clinical and preventative effectiveness, delayed development of the diabetes-related complications.
8 cl
